nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—Pentostatin—hematologic cancer	0.141	0.635	CbGbCtD
Vidarabine—Pentostatin—hematologic cancer	0.0883	0.217	CrCtD
Vidarabine—ADA—Nelarabine—hematologic cancer	0.081	0.365	CbGbCtD
Vidarabine—Clofarabine—hematologic cancer	0.0787	0.194	CrCtD
Vidarabine—Nelarabine—hematologic cancer	0.074	0.182	CrCtD
Vidarabine—Fludarabine—hematologic cancer	0.0578	0.142	CrCtD
Vidarabine—Cytarabine—hematologic cancer	0.0545	0.134	CrCtD
Vidarabine—Cladribine—hematologic cancer	0.0531	0.131	CrCtD
Vidarabine—Adenosine triphosphate—Nelarabine—hematologic cancer	0.00645	0.0238	CrCrCtD
Vidarabine—Ribavirin—Clofarabine—hematologic cancer	0.00636	0.0234	CrCrCtD
Vidarabine—Glucosamine—Cytarabine—hematologic cancer	0.00633	0.0233	CrCrCtD
Vidarabine—Ribavirin—Nelarabine—hematologic cancer	0.00598	0.022	CrCrCtD
Vidarabine—Regadenoson—Clofarabine—hematologic cancer	0.00593	0.0218	CrCrCtD
Vidarabine—S-Adenosylmethionine—Clofarabine—hematologic cancer	0.00593	0.0218	CrCrCtD
Vidarabine—Clofarabine—Nelarabine—hematologic cancer	0.00558	0.0205	CrCrCtD
Vidarabine—S-Adenosylmethionine—Nelarabine—hematologic cancer	0.00558	0.0205	CrCrCtD
Vidarabine—Regadenoson—Nelarabine—hematologic cancer	0.00558	0.0205	CrCrCtD
Vidarabine—Fludarabine—Clofarabine—hematologic cancer	0.00556	0.0205	CrCrCtD
Vidarabine—Adenosine—Pentostatin—hematologic cancer	0.00529	0.0195	CrCrCtD
Vidarabine—Azacitidine—Pentostatin—hematologic cancer	0.00529	0.0195	CrCrCtD
Vidarabine—Cladribine—Pentostatin—hematologic cancer	0.00529	0.0195	CrCrCtD
Vidarabine—Adenosine monophosphate—Clofarabine—hematologic cancer	0.00524	0.0193	CrCrCtD
Vidarabine—Nelarabine—Clofarabine—hematologic cancer	0.00524	0.0193	CrCrCtD
Vidarabine—Fludarabine—Nelarabine—hematologic cancer	0.00523	0.0193	CrCrCtD
Vidarabine—Pentostatin—Cladribine—hematologic cancer	0.00504	0.0186	CrCrCtD
Vidarabine—Adenosine triphosphate—Fludarabine—hematologic cancer	0.00504	0.0185	CrCrCtD
Vidarabine—Decitabine—Pentostatin—hematologic cancer	0.00504	0.0185	CrCrCtD
Vidarabine—Cytarabine—Clofarabine—hematologic cancer	0.00496	0.0183	CrCrCtD
Vidarabine—Adenosine monophosphate—Nelarabine—hematologic cancer	0.00493	0.0181	CrCrCtD
Vidarabine—Azacitidine—Clofarabine—hematologic cancer	0.00471	0.0173	CrCrCtD
Vidarabine—Adenosine—Clofarabine—hematologic cancer	0.00471	0.0173	CrCrCtD
Vidarabine—Cladribine—Clofarabine—hematologic cancer	0.00471	0.0173	CrCrCtD
Vidarabine—Ribavirin—Fludarabine—hematologic cancer	0.00467	0.0172	CrCrCtD
Vidarabine—Cytarabine—Nelarabine—hematologic cancer	0.00466	0.0172	CrCrCtD
Vidarabine—Decitabine—Clofarabine—hematologic cancer	0.00449	0.0165	CrCrCtD
Vidarabine—Cladribine—Nelarabine—hematologic cancer	0.00443	0.0163	CrCrCtD
Vidarabine—Adenosine—Nelarabine—hematologic cancer	0.00443	0.0163	CrCrCtD
Vidarabine—Azacitidine—Nelarabine—hematologic cancer	0.00443	0.0163	CrCrCtD
Vidarabine—Ribavirin—Cytarabine—hematologic cancer	0.00441	0.0162	CrCrCtD
Vidarabine—S-Adenosylmethionine—Fludarabine—hematologic cancer	0.00435	0.016	CrCrCtD
Vidarabine—Regadenoson—Fludarabine—hematologic cancer	0.00435	0.016	CrCrCtD
Vidarabine—Clofarabine—Fludarabine—hematologic cancer	0.00435	0.016	CrCrCtD
Vidarabine—Decitabine—Nelarabine—hematologic cancer	0.00422	0.0155	CrCrCtD
Vidarabine—S-Adenosylmethionine—Cytarabine—hematologic cancer	0.00411	0.0151	CrCrCtD
Vidarabine—Clofarabine—Cytarabine—hematologic cancer	0.00411	0.0151	CrCrCtD
Vidarabine—Regadenoson—Cytarabine—hematologic cancer	0.00411	0.0151	CrCrCtD
Vidarabine—Regadenoson—Cladribine—hematologic cancer	0.00401	0.0148	CrCrCtD
Vidarabine—Clofarabine—Cladribine—hematologic cancer	0.00401	0.0148	CrCrCtD
Vidarabine—Fludarabine—Cytarabine—hematologic cancer	0.00386	0.0142	CrCrCtD
Vidarabine—Adenosine monophosphate—Fludarabine—hematologic cancer	0.00385	0.0142	CrCrCtD
Vidarabine—Nelarabine—Fludarabine—hematologic cancer	0.00385	0.0142	CrCrCtD
Vidarabine—Fludarabine—Cladribine—hematologic cancer	0.00376	0.0138	CrCrCtD
Vidarabine—Cytarabine—Fludarabine—hematologic cancer	0.00364	0.0134	CrCrCtD
Vidarabine—Adenosine monophosphate—Cytarabine—hematologic cancer	0.00363	0.0134	CrCrCtD
Vidarabine—Nelarabine—Cytarabine—hematologic cancer	0.00363	0.0134	CrCrCtD
Vidarabine—Adenosine monophosphate—Cladribine—hematologic cancer	0.00354	0.013	CrCrCtD
Vidarabine—Nelarabine—Cladribine—hematologic cancer	0.00354	0.013	CrCrCtD
Vidarabine—Azacitidine—Fludarabine—hematologic cancer	0.00346	0.0127	CrCrCtD
Vidarabine—Adenosine—Fludarabine—hematologic cancer	0.00346	0.0127	CrCrCtD
Vidarabine—Cladribine—Fludarabine—hematologic cancer	0.00346	0.0127	CrCrCtD
Vidarabine—Cytarabine—Gemcitabine—hematologic cancer	0.00344	0.0127	CrCrCtD
Vidarabine—Azacitidine—Gemcitabine—hematologic cancer	0.00327	0.012	CrCrCtD
Vidarabine—Azacitidine—Cytarabine—hematologic cancer	0.00327	0.012	CrCrCtD
Vidarabine—Adenosine—Cytarabine—hematologic cancer	0.00327	0.012	CrCrCtD
Vidarabine—Adenosine—Cladribine—hematologic cancer	0.00318	0.0117	CrCrCtD
Vidarabine—Azacitidine—Cladribine—hematologic cancer	0.00318	0.0117	CrCrCtD
Vidarabine—Decitabine—Gemcitabine—hematologic cancer	0.00311	0.0115	CrCrCtD
Vidarabine—Decitabine—Cytarabine—hematologic cancer	0.00311	0.0115	CrCrCtD
Vidarabine—Decitabine—Cladribine—hematologic cancer	0.00303	0.0112	CrCrCtD
Vidarabine—ADA—hematopoietic system—hematologic cancer	0.000993	0.0751	CbGeAlD
Vidarabine—ADORA2A—hematopoietic system—hematologic cancer	0.000903	0.0683	CbGeAlD
Vidarabine—ADK—hematopoietic system—hematologic cancer	0.000811	0.0614	CbGeAlD
Vidarabine—DPP4—hematopoietic system—hematologic cancer	0.000786	0.0595	CbGeAlD
Vidarabine—ADORA2A—gonad—hematologic cancer	0.000687	0.0519	CbGeAlD
Vidarabine—ADA—blood—hematologic cancer	0.000658	0.0497	CbGeAlD
Vidarabine—ADA—bone marrow—hematologic cancer	0.000636	0.0481	CbGeAlD
Vidarabine—ADK—gonad—hematologic cancer	0.000617	0.0466	CbGeAlD
Vidarabine—ADORA2A—blood—hematologic cancer	0.000598	0.0453	CbGeAlD
Vidarabine—ADA—lung—hematologic cancer	0.000576	0.0436	CbGeAlD
Vidarabine—ADA—testis—hematologic cancer	0.000544	0.0411	CbGeAlD
Vidarabine—ADK—blood—hematologic cancer	0.000537	0.0406	CbGeAlD
Vidarabine—DPP4—blood—hematologic cancer	0.000521	0.0394	CbGeAlD
Vidarabine—ADK—bone marrow—hematologic cancer	0.00052	0.0393	CbGeAlD
Vidarabine—DPP4—bone marrow—hematologic cancer	0.000504	0.0381	CbGeAlD
Vidarabine—ADORA2A—testis—hematologic cancer	0.000495	0.0374	CbGeAlD
Vidarabine—ADK—lung—hematologic cancer	0.000471	0.0356	CbGeAlD
Vidarabine—DPP4—lung—hematologic cancer	0.000457	0.0345	CbGeAlD
Vidarabine—ADK—testis—hematologic cancer	0.000444	0.0336	CbGeAlD
Vidarabine—DPP4—testis—hematologic cancer	0.000431	0.0326	CbGeAlD
Vidarabine—ADA—lymph node—hematologic cancer	0.000394	0.0298	CbGeAlD
Vidarabine—ADK—lymph node—hematologic cancer	0.000322	0.0244	CbGeAlD
Vidarabine—DPP4—lymph node—hematologic cancer	0.000312	0.0236	CbGeAlD
Vidarabine—Azacitidine—DNMT3A—hematologic cancer	0.000192	0.0934	CrCbGaD
Vidarabine—Decitabine—DNMT3A—hematologic cancer	0.000187	0.0911	CrCbGaD
Vidarabine—Azacitidine—CDA—hematologic cancer	0.000171	0.0832	CrCbGaD
Vidarabine—Decitabine—DCK—hematologic cancer	0.000147	0.0715	CrCbGaD
Vidarabine—Nelarabine—DCK—hematologic cancer	0.000142	0.0689	CrCbGaD
Vidarabine—Clofarabine—DCK—hematologic cancer	0.000138	0.067	CrCbGaD
Vidarabine—Fludarabine—DCK—hematologic cancer	0.000133	0.0649	CrCbGaD
Vidarabine—Adenosine triphosphate—ASNS—hematologic cancer	0.000101	0.0491	CrCbGaD
Vidarabine—Cytarabine—CDA—hematologic cancer	9.76e-05	0.0475	CrCbGaD
Vidarabine—Adenosine monophosphate—CREB1—hematologic cancer	8.81e-05	0.0429	CrCbGaD
Vidarabine—Glucosamine—IFNG—hematologic cancer	8.81e-05	0.0429	CrCbGaD
Vidarabine—Cytarabine—DCK—hematologic cancer	8.59e-05	0.0418	CrCbGaD
Vidarabine—Cladribine—DCK—hematologic cancer	7.91e-05	0.0385	CrCbGaD
Vidarabine—Adenosine triphosphate—ABL2—hematologic cancer	7.64e-05	0.0372	CrCbGaD
Vidarabine—Adenosine triphosphate—ALK—hematologic cancer	4.63e-05	0.0225	CrCbGaD
Vidarabine—Glucosamine—TNF—hematologic cancer	3.69e-05	0.018	CrCbGaD
Vidarabine—Adenosine triphosphate—AKT1—hematologic cancer	3.61e-05	0.0176	CrCbGaD
Vidarabine—Adenosine monophosphate—SRC—hematologic cancer	3.56e-05	0.0173	CrCbGaD
Vidarabine—Adenosine triphosphate—ABL1—hematologic cancer	3.41e-05	0.0166	CrCbGaD
Vidarabine—Adenosine monophosphate—PDE4B—hematologic cancer	3.18e-05	0.0155	CrCbGaD
Vidarabine—Clofarabine—ABCG2—hematologic cancer	3.1e-05	0.0151	CrCbGaD
Vidarabine—Cytarabine—SLC22A1—hematologic cancer	2.77e-05	0.0135	CrCbGaD
Vidarabine—Cladribine—SLC22A1—hematologic cancer	2.55e-05	0.0124	CrCbGaD
Vidarabine—Cladribine—ABCG2—hematologic cancer	1.78e-05	0.00868	CrCbGaD
Vidarabine—Dermatitis—Thalidomide—hematologic cancer	1.34e-05	0.000241	CcSEcCtD
Vidarabine—Dizziness—Alitretinoin—hematologic cancer	1.34e-05	0.000241	CcSEcCtD
Vidarabine—Headache—Thalidomide—hematologic cancer	1.34e-05	0.00024	CcSEcCtD
Vidarabine—Pain—Prednisolone—hematologic cancer	1.34e-05	0.00024	CcSEcCtD
Vidarabine—Sweating—Epirubicin—hematologic cancer	1.34e-05	0.00024	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—hematologic cancer	1.34e-05	0.00024	CcSEcCtD
Vidarabine—Asthenia—Gemcitabine—hematologic cancer	1.33e-05	0.000239	CcSEcCtD
Vidarabine—Dizziness—Ifosfamide—hematologic cancer	1.33e-05	0.000238	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—hematologic cancer	1.31e-05	0.000236	CcSEcCtD
Vidarabine—Nausea—Thiotepa—hematologic cancer	1.31e-05	0.000235	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	1.31e-05	0.000235	CcSEcCtD
Vidarabine—Anaphylactic shock—Betamethasone—hematologic cancer	1.3e-05	0.000234	CcSEcCtD
Vidarabine—Anaphylactic shock—Dexamethasone—hematologic cancer	1.3e-05	0.000234	CcSEcCtD
Vidarabine—Vomiting—Carmustine—hematologic cancer	1.3e-05	0.000234	CcSEcCtD
Vidarabine—Dizziness—Vincristine—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Rash—Carmustine—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Dermatitis—Carmustine—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Vomiting—Alitretinoin—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Paraesthesia—Triamcinolone—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—hematologic cancer	1.29e-05	0.000232	CcSEcCtD
Vidarabine—Headache—Carmustine—hematologic cancer	1.28e-05	0.000231	CcSEcCtD
Vidarabine—Shock—Betamethasone—hematologic cancer	1.28e-05	0.000231	CcSEcCtD
Vidarabine—Shock—Dexamethasone—hematologic cancer	1.28e-05	0.000231	CcSEcCtD
Vidarabine—Dyspnoea—Triamcinolone—hematologic cancer	1.28e-05	0.00023	CcSEcCtD
Vidarabine—Rash—Alitretinoin—hematologic cancer	1.28e-05	0.00023	CcSEcCtD
Vidarabine—Agitation—Prednisone—hematologic cancer	1.28e-05	0.00023	CcSEcCtD
Vidarabine—Dermatitis—Alitretinoin—hematologic cancer	1.28e-05	0.00023	CcSEcCtD
Vidarabine—Vomiting—Ifosfamide—hematologic cancer	1.28e-05	0.000229	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—hematologic cancer	1.27e-05	0.000229	CcSEcCtD
Vidarabine—Tachycardia—Betamethasone—hematologic cancer	1.27e-05	0.000229	CcSEcCtD
Vidarabine—Tachycardia—Dexamethasone—hematologic cancer	1.27e-05	0.000229	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—hematologic cancer	1.27e-05	0.000229	CcSEcCtD
Vidarabine—Headache—Alitretinoin—hematologic cancer	1.27e-05	0.000228	CcSEcCtD
Vidarabine—Angioedema—Prednisone—hematologic cancer	1.27e-05	0.000228	CcSEcCtD
Vidarabine—Nausea—Thalidomide—hematologic cancer	1.27e-05	0.000228	CcSEcCtD
Vidarabine—Rash—Ifosfamide—hematologic cancer	1.26e-05	0.000227	CcSEcCtD
Vidarabine—Dermatitis—Ifosfamide—hematologic cancer	1.26e-05	0.000227	CcSEcCtD
Vidarabine—Hyperhidrosis—Betamethasone—hematologic cancer	1.26e-05	0.000227	CcSEcCtD
Vidarabine—Hyperhidrosis—Dexamethasone—hematologic cancer	1.26e-05	0.000227	CcSEcCtD
Vidarabine—Dizziness—Irinotecan—hematologic cancer	1.26e-05	0.000226	CcSEcCtD
Vidarabine—Urticaria—Etoposide—hematologic cancer	1.26e-05	0.000226	CcSEcCtD
Vidarabine—Syncope—Prednisone—hematologic cancer	1.25e-05	0.000224	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—hematologic cancer	1.25e-05	0.000224	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—hematologic cancer	1.24e-05	0.000224	CcSEcCtD
Vidarabine—Vomiting—Vincristine—hematologic cancer	1.24e-05	0.000223	CcSEcCtD
Vidarabine—Urticaria—Prednisolone—hematologic cancer	1.24e-05	0.000223	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—hematologic cancer	1.24e-05	0.000223	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—hematologic cancer	1.24e-05	0.000223	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—hematologic cancer	1.24e-05	0.000222	CcSEcCtD
Vidarabine—Rash—Vincristine—hematologic cancer	1.23e-05	0.000222	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—hematologic cancer	1.23e-05	0.000221	CcSEcCtD
Vidarabine—Pain—Triamcinolone—hematologic cancer	1.23e-05	0.000221	CcSEcCtD
Vidarabine—Headache—Vincristine—hematologic cancer	1.23e-05	0.00022	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—hematologic cancer	1.22e-05	0.00022	CcSEcCtD
Vidarabine—Hypotension—Dexamethasone—hematologic cancer	1.22e-05	0.000219	CcSEcCtD
Vidarabine—Hypotension—Betamethasone—hematologic cancer	1.22e-05	0.000219	CcSEcCtD
Vidarabine—Nausea—Carmustine—hematologic cancer	1.22e-05	0.000219	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—hematologic cancer	1.21e-05	0.000218	CcSEcCtD
Vidarabine—Vomiting—Irinotecan—hematologic cancer	1.21e-05	0.000218	CcSEcCtD
Vidarabine—Nausea—Alitretinoin—hematologic cancer	1.21e-05	0.000217	CcSEcCtD
Vidarabine—Convulsion—Prednisone—hematologic cancer	1.21e-05	0.000217	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Hypertension—Prednisone—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Rash—Irinotecan—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Dermatitis—Irinotecan—hematologic cancer	1.2e-05	0.000216	CcSEcCtD
Vidarabine—Headache—Irinotecan—hematologic cancer	1.19e-05	0.000214	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—hematologic cancer	1.19e-05	0.000214	CcSEcCtD
Vidarabine—Nausea—Ifosfamide—hematologic cancer	1.19e-05	0.000214	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.19e-05	0.000213	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.19e-05	0.000213	CcSEcCtD
Vidarabine—Anxiety—Prednisone—hematologic cancer	1.18e-05	0.000212	CcSEcCtD
Vidarabine—Vomiting—Gemcitabine—hematologic cancer	1.18e-05	0.000212	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—hematologic cancer	1.18e-05	0.000212	CcSEcCtD
Vidarabine—Paraesthesia—Betamethasone—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Paraesthesia—Dexamethasone—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Discomfort—Prednisone—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Rash—Gemcitabine—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Dermatitis—Gemcitabine—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—hematologic cancer	1.17e-05	0.00021	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—hematologic cancer	1.17e-05	0.000209	CcSEcCtD
Vidarabine—Headache—Gemcitabine—hematologic cancer	1.16e-05	0.000209	CcSEcCtD
Vidarabine—Nausea—Vincristine—hematologic cancer	1.16e-05	0.000209	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—hematologic cancer	1.16e-05	0.000208	CcSEcCtD
Vidarabine—Flushing—Epirubicin—hematologic cancer	1.16e-05	0.000208	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisolone—hematologic cancer	1.15e-05	0.000207	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—hematologic cancer	1.15e-05	0.000207	CcSEcCtD
Vidarabine—Urticaria—Triamcinolone—hematologic cancer	1.14e-05	0.000205	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—hematologic cancer	1.14e-05	0.000205	CcSEcCtD
Vidarabine—Asthenia—Etoposide—hematologic cancer	1.14e-05	0.000204	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—hematologic cancer	1.14e-05	0.000204	CcSEcCtD
Vidarabine—Nausea—Irinotecan—hematologic cancer	1.13e-05	0.000203	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—hematologic cancer	1.13e-05	0.000203	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—hematologic cancer	1.13e-05	0.000202	CcSEcCtD
Vidarabine—Back pain—Methotrexate—hematologic cancer	1.12e-05	0.000202	CcSEcCtD
Vidarabine—Shock—Prednisone—hematologic cancer	1.12e-05	0.000201	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—hematologic cancer	1.12e-05	0.000201	CcSEcCtD
Vidarabine—Pain—Betamethasone—hematologic cancer	1.12e-05	0.0002	CcSEcCtD
Vidarabine—Pain—Dexamethasone—hematologic cancer	1.12e-05	0.0002	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—hematologic cancer	1.11e-05	0.000199	CcSEcCtD
Vidarabine—Nausea—Gemcitabine—hematologic cancer	1.1e-05	0.000198	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—hematologic cancer	1.1e-05	0.000198	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—hematologic cancer	1.1e-05	0.000197	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—hematologic cancer	1.1e-05	0.000197	CcSEcCtD
Vidarabine—Rash—Cisplatin—hematologic cancer	1.09e-05	0.000196	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—hematologic cancer	1.09e-05	0.000196	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—hematologic cancer	1.08e-05	0.000194	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—hematologic cancer	1.07e-05	0.000193	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—hematologic cancer	1.07e-05	0.000193	CcSEcCtD
Vidarabine—Tension—Epirubicin—hematologic cancer	1.07e-05	0.000192	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—hematologic cancer	1.07e-05	0.000191	CcSEcCtD
Vidarabine—Hypersensitivity—Triamcinolone—hematologic cancer	1.06e-05	0.00019	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—hematologic cancer	1.06e-05	0.00019	CcSEcCtD
Vidarabine—Back pain—Epirubicin—hematologic cancer	1.05e-05	0.000189	CcSEcCtD
Vidarabine—Dizziness—Etoposide—hematologic cancer	1.05e-05	0.000188	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—hematologic cancer	1.04e-05	0.000187	CcSEcCtD
Vidarabine—Urticaria—Dexamethasone—hematologic cancer	1.04e-05	0.000186	CcSEcCtD
Vidarabine—Urticaria—Betamethasone—hematologic cancer	1.04e-05	0.000186	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.03e-05	0.000186	CcSEcCtD
Vidarabine—Dizziness—Prednisolone—hematologic cancer	1.03e-05	0.000186	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—hematologic cancer	1.03e-05	0.000186	CcSEcCtD
Vidarabine—Asthenia—Triamcinolone—hematologic cancer	1.03e-05	0.000185	CcSEcCtD
Vidarabine—Nausea—Cisplatin—hematologic cancer	1.03e-05	0.000185	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—hematologic cancer	1.03e-05	0.000184	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—hematologic cancer	1.02e-05	0.000183	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—hematologic cancer	1.02e-05	0.000348	CbGpPWpGaD
Vidarabine—Cough—Methotrexate—hematologic cancer	1.01e-05	0.000182	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—IL6R—hematologic cancer	1.01e-05	0.000346	CbGpPWpGaD
Vidarabine—Convulsion—Methotrexate—hematologic cancer	1.01e-05	0.000181	CcSEcCtD
Vidarabine—Vomiting—Etoposide—hematologic cancer	1.01e-05	0.000181	CcSEcCtD
Vidarabine—ADA—Metabolism—SDC1—hematologic cancer	1.01e-05	0.000344	CbGpPWpGaD
Vidarabine—Agitation—Epirubicin—hematologic cancer	1e-05	0.00018	CcSEcCtD
Vidarabine—Rash—Etoposide—hematologic cancer	9.99e-06	0.00018	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—hematologic cancer	9.98e-06	0.000179	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—ADCY7—hematologic cancer	9.96e-06	0.000341	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ABCB1—hematologic cancer	9.94e-06	0.00034	CbGpPWpGaD
Vidarabine—Headache—Etoposide—hematologic cancer	9.93e-06	0.000178	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—hematologic cancer	9.9e-06	0.000178	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—HDAC10—hematologic cancer	9.9e-06	0.000339	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUN—hematologic cancer	9.88e-06	0.000338	CbGpPWpGaD
Vidarabine—Tension—Doxorubicin—hematologic cancer	9.88e-06	0.000178	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—hematologic cancer	9.86e-06	0.000177	CcSEcCtD
Vidarabine—Rash—Prednisolone—hematologic cancer	9.85e-06	0.000177	CcSEcCtD
Vidarabine—Dermatitis—Prednisolone—hematologic cancer	9.85e-06	0.000177	CcSEcCtD
Vidarabine—Headache—Prednisolone—hematologic cancer	9.79e-06	0.000176	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—hematologic cancer	9.78e-06	0.000176	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—hematologic cancer	9.78e-06	0.000176	CcSEcCtD
Vidarabine—Syncope—Epirubicin—hematologic cancer	9.76e-06	0.000175	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—hematologic cancer	9.74e-06	0.000175	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTM1—hematologic cancer	9.65e-06	0.00033	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NCOR1—hematologic cancer	9.65e-06	0.00033	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAP2K1—hematologic cancer	9.64e-06	0.00033	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PDE4B—hematologic cancer	9.62e-06	0.000329	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CNR2—hematologic cancer	9.62e-06	0.000329	CbGpPWpGaD
Vidarabine—Palpitations—Epirubicin—hematologic cancer	9.62e-06	0.000173	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CD—hematologic cancer	9.57e-06	0.000328	CbGpPWpGaD
Vidarabine—Loss of consciousness—Epirubicin—hematologic cancer	9.57e-06	0.000172	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—hematologic cancer	9.56e-06	0.000327	CbGpPWpGaD
Vidarabine—Dizziness—Triamcinolone—hematologic cancer	9.5e-06	0.000171	CcSEcCtD
Vidarabine—Cough—Epirubicin—hematologic cancer	9.5e-06	0.000171	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—hematologic cancer	9.49e-06	0.000171	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—hematologic cancer	9.49e-06	0.000171	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—RAC2—hematologic cancer	9.47e-06	0.000324	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	9.44e-06	0.000323	CbGpPWpGaD
Vidarabine—Convulsion—Epirubicin—hematologic cancer	9.43e-06	0.000169	CcSEcCtD
Vidarabine—Nausea—Etoposide—hematologic cancer	9.41e-06	0.000169	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—hematologic cancer	9.4e-06	0.000169	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—hematologic cancer	9.39e-06	0.000322	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—hematologic cancer	9.37e-06	0.000321	CbGpPWpGaD
Vidarabine—Asthenia—Betamethasone—hematologic cancer	9.36e-06	0.000168	CcSEcCtD
Vidarabine—Asthenia—Dexamethasone—hematologic cancer	9.36e-06	0.000168	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—MAPK8—hematologic cancer	9.35e-06	0.00032	CbGpPWpGaD
Vidarabine—Nausea—Prednisolone—hematologic cancer	9.28e-06	0.000167	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—hematologic cancer	9.27e-06	0.000166	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—hematologic cancer	9.25e-06	0.000166	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—hematologic cancer	9.23e-06	0.000166	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—hematologic cancer	9.18e-06	0.000165	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—FGF2—hematologic cancer	9.17e-06	0.000314	CbGpPWpGaD
Vidarabine—Discomfort—Epirubicin—hematologic cancer	9.15e-06	0.000164	CcSEcCtD
Vidarabine—Vomiting—Triamcinolone—hematologic cancer	9.14e-06	0.000164	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—hematologic cancer	9.12e-06	0.000312	CbGpPWpGaD
Vidarabine—Rash—Triamcinolone—hematologic cancer	9.06e-06	0.000163	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—hematologic cancer	9.06e-06	0.000163	CcSEcCtD
Vidarabine—Dermatitis—Triamcinolone—hematologic cancer	9.05e-06	0.000163	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—ARHGEF12—hematologic cancer	9.05e-06	0.00031	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADCY7—hematologic cancer	9.05e-06	0.00031	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3R1—hematologic cancer	9.04e-06	0.000309	CbGpPWpGaD
Vidarabine—Syncope—Doxorubicin—hematologic cancer	9.03e-06	0.000162	CcSEcCtD
Vidarabine—Urticaria—Prednisone—hematologic cancer	9.02e-06	0.000162	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—PTHLH—hematologic cancer	9.01e-06	0.000308	CbGpPWpGaD
Vidarabine—Headache—Triamcinolone—hematologic cancer	9e-06	0.000162	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—hematologic cancer	8.9e-06	0.00016	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—hematologic cancer	8.88e-06	0.00016	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—hematologic cancer	8.87e-06	0.000159	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—hematologic cancer	8.85e-06	0.000159	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—ARHGEF1—hematologic cancer	8.82e-06	0.000302	CbGpPWpGaD
Vidarabine—Cough—Doxorubicin—hematologic cancer	8.79e-06	0.000158	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—JAK2—hematologic cancer	8.78e-06	0.000301	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTGER4—hematologic cancer	8.77e-06	0.0003	CbGpPWpGaD
Vidarabine—Shock—Epirubicin—hematologic cancer	8.74e-06	0.000157	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—hematologic cancer	8.72e-06	0.000157	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—hematologic cancer	8.69e-06	0.000156	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—hematologic cancer	8.69e-06	0.000298	CbGpPWpGaD
Vidarabine—Tachycardia—Epirubicin—hematologic cancer	8.67e-06	0.000156	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.65e-06	0.000155	CcSEcCtD
Vidarabine—Dizziness—Betamethasone—hematologic cancer	8.62e-06	0.000155	CcSEcCtD
Vidarabine—Dizziness—Dexamethasone—hematologic cancer	8.62e-06	0.000155	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—hematologic cancer	8.59e-06	0.000154	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—hematologic cancer	8.58e-06	0.000293	CbGpPWpGaD
Vidarabine—Chest pain—Doxorubicin—hematologic cancer	8.57e-06	0.000154	CcSEcCtD
Vidarabine—ADA—Metabolism—NQO1—hematologic cancer	8.56e-06	0.000293	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CD44—hematologic cancer	8.56e-06	0.000293	CbGpPWpGaD
Vidarabine—Anxiety—Doxorubicin—hematologic cancer	8.54e-06	0.000154	CcSEcCtD
Vidarabine—Nausea—Triamcinolone—hematologic cancer	8.54e-06	0.000153	CcSEcCtD
Vidarabine—ADK—Metabolism—MTHFR—hematologic cancer	8.53e-06	0.000292	CbGpPWpGaD
Vidarabine—Paraesthesia—Methotrexate—hematologic cancer	8.52e-06	0.000153	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—hematologic cancer	8.47e-06	0.000152	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—hematologic cancer	8.46e-06	0.000152	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—hematologic cancer	8.44e-06	0.000152	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—hematologic cancer	8.38e-06	0.000151	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—hematologic cancer	8.38e-06	0.000287	CbGpPWpGaD
Vidarabine—Hypersensitivity—Prednisone—hematologic cancer	8.37e-06	0.00015	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—hematologic cancer	8.36e-06	0.000286	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—hematologic cancer	8.34e-06	0.000286	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—hematologic cancer	8.34e-06	0.000286	CbGpPWpGaD
Vidarabine—Hypotension—Epirubicin—hematologic cancer	8.3e-06	0.000149	CcSEcCtD
Vidarabine—Vomiting—Betamethasone—hematologic cancer	8.29e-06	0.000149	CcSEcCtD
Vidarabine—Vomiting—Dexamethasone—hematologic cancer	8.29e-06	0.000149	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—CCL3—hematologic cancer	8.27e-06	0.000283	CbGpPWpGaD
Vidarabine—Rash—Dexamethasone—hematologic cancer	8.22e-06	0.000148	CcSEcCtD
Vidarabine—Rash—Betamethasone—hematologic cancer	8.22e-06	0.000148	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—hematologic cancer	8.22e-06	0.000148	CcSEcCtD
Vidarabine—Dermatitis—Betamethasone—hematologic cancer	8.21e-06	0.000148	CcSEcCtD
Vidarabine—Dermatitis—Dexamethasone—hematologic cancer	8.21e-06	0.000148	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PTHLH—hematologic cancer	8.18e-06	0.00028	CbGpPWpGaD
Vidarabine—Headache—Betamethasone—hematologic cancer	8.17e-06	0.000147	CcSEcCtD
Vidarabine—Headache—Dexamethasone—hematologic cancer	8.17e-06	0.000147	CcSEcCtD
Vidarabine—Asthenia—Prednisone—hematologic cancer	8.15e-06	0.000146	CcSEcCtD
Vidarabine—Pain—Methotrexate—hematologic cancer	8.12e-06	0.000146	CcSEcCtD
Vidarabine—ADA—Metabolism—CYCS—hematologic cancer	8.1e-06	0.000277	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.09e-06	0.000145	CcSEcCtD
Vidarabine—Shock—Doxorubicin—hematologic cancer	8.09e-06	0.000145	CcSEcCtD
Vidarabine—ADA—Metabolism—HSP90AA1—hematologic cancer	8.04e-06	0.000275	CbGpPWpGaD
Vidarabine—Tachycardia—Doxorubicin—hematologic cancer	8.02e-06	0.000144	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—hematologic cancer	8.01e-06	0.000274	CbGpPWpGaD
Vidarabine—Paraesthesia—Epirubicin—hematologic cancer	7.98e-06	0.000143	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PTGER4—hematologic cancer	7.96e-06	0.000273	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Doxorubicin—hematologic cancer	7.95e-06	0.000143	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—hematologic cancer	7.92e-06	0.000142	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—AGRN—hematologic cancer	7.91e-06	0.000271	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL17—hematologic cancer	7.91e-06	0.000271	CbGpPWpGaD
Vidarabine—Somnolence—Epirubicin—hematologic cancer	7.9e-06	0.000142	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—hematologic cancer	7.83e-06	0.000268	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR5—hematologic cancer	7.77e-06	0.000266	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCR4—hematologic cancer	7.75e-06	0.000265	CbGpPWpGaD
Vidarabine—Nausea—Dexamethasone—hematologic cancer	7.75e-06	0.000139	CcSEcCtD
Vidarabine—Nausea—Betamethasone—hematologic cancer	7.75e-06	0.000139	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—hematologic cancer	7.68e-06	0.000138	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—hematologic cancer	7.67e-06	0.000263	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEF1—hematologic cancer	7.63e-06	0.000261	CbGpPWpGaD
Vidarabine—Pain—Epirubicin—hematologic cancer	7.6e-06	0.000136	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—hematologic cancer	7.54e-06	0.000135	CcSEcCtD
Vidarabine—Dizziness—Prednisone—hematologic cancer	7.51e-06	0.000135	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—GNA13—hematologic cancer	7.5e-06	0.000257	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.49e-06	0.000135	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—IL3—hematologic cancer	7.47e-06	0.000256	CbGpPWpGaD
Vidarabine—Paraesthesia—Doxorubicin—hematologic cancer	7.38e-06	0.000133	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—TIAM1—hematologic cancer	7.38e-06	0.000253	CbGpPWpGaD
Vidarabine—Dyspnoea—Doxorubicin—hematologic cancer	7.33e-06	0.000132	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—hematologic cancer	7.31e-06	0.000131	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—hematologic cancer	7.23e-06	0.000247	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—RASGRP1—hematologic cancer	7.23e-06	0.000247	CbGpPWpGaD
Vidarabine—Vomiting—Prednisone—hematologic cancer	7.22e-06	0.00013	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—hematologic cancer	7.21e-06	0.000247	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—hematologic cancer	7.2e-06	0.000246	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL2—hematologic cancer	7.18e-06	0.000246	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CG—hematologic cancer	7.16e-06	0.000245	CbGpPWpGaD
Vidarabine—Rash—Prednisone—hematologic cancer	7.16e-06	0.000129	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—JAK3—hematologic cancer	7.15e-06	0.000245	CbGpPWpGaD
Vidarabine—Dermatitis—Prednisone—hematologic cancer	7.15e-06	0.000129	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTP1—hematologic cancer	7.14e-06	0.000244	CbGpPWpGaD
Vidarabine—Headache—Prednisone—hematologic cancer	7.11e-06	0.000128	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—hematologic cancer	7.06e-06	0.000127	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—MAPK8—hematologic cancer	7.05e-06	0.000241	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCR4—hematologic cancer	7.04e-06	0.000241	CbGpPWpGaD
Vidarabine—Pain—Doxorubicin—hematologic cancer	7.03e-06	0.000126	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—hematologic cancer	6.99e-06	0.000126	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—CCR7—hematologic cancer	6.86e-06	0.000235	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL13—hematologic cancer	6.86e-06	0.000235	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—hematologic cancer	6.81e-06	0.000122	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—IL3—hematologic cancer	6.78e-06	0.000232	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NCOR2—hematologic cancer	6.77e-06	0.000232	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—hematologic cancer	6.76e-06	0.000231	CbGpPWpGaD
Vidarabine—Nausea—Prednisone—hematologic cancer	6.75e-06	0.000121	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—SRC—hematologic cancer	6.69e-06	0.000229	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL3RA—hematologic cancer	6.68e-06	0.000229	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CRKL—hematologic cancer	6.68e-06	0.000229	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CREBBP—hematologic cancer	6.64e-06	0.000227	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—hematologic cancer	6.61e-06	0.000226	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RASGRP1—hematologic cancer	6.56e-06	0.000225	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—hematologic cancer	6.56e-06	0.000224	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOR1—hematologic cancer	6.56e-06	0.000224	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—hematologic cancer	6.54e-06	0.000118	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—hematologic cancer	6.53e-06	0.000117	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—hematologic cancer	6.52e-06	0.000223	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GRB2—hematologic cancer	6.5e-06	0.000222	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RGS2—hematologic cancer	6.45e-06	0.000221	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—hematologic cancer	6.45e-06	0.000221	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—hematologic cancer	6.43e-06	0.00022	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TRH—hematologic cancer	6.38e-06	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TRIO—hematologic cancer	6.38e-06	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CMA1—hematologic cancer	6.38e-06	0.000218	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—hematologic cancer	6.37e-06	0.000115	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCB1—hematologic cancer	6.31e-06	0.00307	CrCbGaD
Vidarabine—ADK—Metabolism—PIK3CD—hematologic cancer	6.3e-06	0.000216	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—hematologic cancer	6.28e-06	0.000113	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—SPHK1—hematologic cancer	6.24e-06	0.000214	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGO2—hematologic cancer	6.24e-06	0.000214	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—hematologic cancer	6.22e-06	0.000213	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LPAR1—hematologic cancer	6.18e-06	0.000211	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HDAC9—hematologic cancer	6.18e-06	0.000211	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK3—hematologic cancer	6.16e-06	0.000211	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—hematologic cancer	6.12e-06	0.000209	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—H3F3B—hematologic cancer	6.11e-06	0.000209	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—hematologic cancer	6.06e-06	0.000109	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—hematologic cancer	6.03e-06	0.000108	CcSEcCtD
Vidarabine—Rash—Methotrexate—hematologic cancer	5.98e-06	0.000108	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—hematologic cancer	5.98e-06	0.000107	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—hematologic cancer	5.97e-06	0.000204	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3R1—hematologic cancer	5.95e-06	0.000204	CbGpPWpGaD
Vidarabine—Headache—Methotrexate—hematologic cancer	5.95e-06	0.000107	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GRB2—hematologic cancer	5.9e-06	0.000202	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—hematologic cancer	5.9e-06	0.000106	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—hematologic cancer	5.87e-06	0.000106	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—hematologic cancer	5.86e-06	0.0002	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CSF2—hematologic cancer	5.81e-06	0.000199	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—hematologic cancer	5.8e-06	0.000198	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDE4B—hematologic cancer	5.68e-06	0.000195	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CNR2—hematologic cancer	5.68e-06	0.000195	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—hematologic cancer	5.65e-06	0.000101	CcSEcCtD
Vidarabine—Nausea—Methotrexate—hematologic cancer	5.64e-06	0.000101	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—FGF19—hematologic cancer	5.64e-06	0.000193	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—JAK1—hematologic cancer	5.6e-06	0.000192	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PRKCG—hematologic cancer	5.6e-06	0.000192	CbGpPWpGaD
Vidarabine—Rash—Epirubicin—hematologic cancer	5.6e-06	0.000101	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—hematologic cancer	5.6e-06	0.000101	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—RAC2—hematologic cancer	5.59e-06	0.000191	CbGpPWpGaD
Vidarabine—Headache—Epirubicin—hematologic cancer	5.56e-06	0.0001	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—DKK1—hematologic cancer	5.55e-06	0.00019	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—hematologic cancer	5.54e-06	0.000189	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT5B—hematologic cancer	5.5e-06	0.000188	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—hematologic cancer	5.49e-06	0.000188	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—hematologic cancer	5.43e-06	9.76e-05	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—hematologic cancer	5.4e-06	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCY7—hematologic cancer	5.34e-06	0.000183	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—hematologic cancer	5.28e-06	9.48e-05	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—CSF2—hematologic cancer	5.27e-06	0.00018	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2RA—hematologic cancer	5.23e-06	0.000179	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—hematologic cancer	5.23e-06	9.39e-05	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—XIAP—hematologic cancer	5.2e-06	0.000178	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—hematologic cancer	5.18e-06	9.31e-05	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—hematologic cancer	5.18e-06	9.3e-05	CcSEcCtD
Vidarabine—Headache—Doxorubicin—hematologic cancer	5.15e-06	9.25e-05	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PRKCG—hematologic cancer	5.09e-06	0.000174	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—JAK1—hematologic cancer	5.09e-06	0.000174	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—hematologic cancer	5.09e-06	0.000174	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SH2B3—hematologic cancer	5.07e-06	0.000173	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMARCA4—hematologic cancer	5.07e-06	0.000173	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GZMB—hematologic cancer	5.03e-06	0.000172	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNA1—hematologic cancer	4.92e-06	0.000168	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EIF4EBP1—hematologic cancer	4.89e-06	0.000167	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL3—hematologic cancer	4.89e-06	0.000167	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HSPB1—hematologic cancer	4.89e-06	0.000167	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—hematologic cancer	4.88e-06	8.77e-05	CcSEcCtD
Vidarabine—ADA—Metabolism—PIK3CG—hematologic cancer	4.87e-06	0.000167	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTHLH—hematologic cancer	4.83e-06	0.000165	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SDC1—hematologic cancer	4.83e-06	0.000165	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2RA—hematologic cancer	4.75e-06	0.000163	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—hematologic cancer	4.74e-06	0.000162	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—hematologic cancer	4.71e-06	0.000161	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTGER4—hematologic cancer	4.7e-06	0.000161	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LCK—hematologic cancer	4.68e-06	0.00016	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—H3F3A—hematologic cancer	4.59e-06	0.000157	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—hematologic cancer	4.52e-06	0.000155	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CREBBP—hematologic cancer	4.51e-06	0.000155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—hematologic cancer	4.5e-06	0.000154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCZ—hematologic cancer	4.46e-06	0.000153	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—hematologic cancer	4.36e-06	0.000149	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PARP1—hematologic cancer	4.31e-06	0.000147	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—hematologic cancer	4.28e-06	0.000147	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FBXW7—hematologic cancer	4.24e-06	0.000145	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—hematologic cancer	4.23e-06	0.000145	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR4—hematologic cancer	4.16e-06	0.000142	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HDAC2—hematologic cancer	4.16e-06	0.000142	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—hematologic cancer	4.15e-06	0.000142	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CBL—hematologic cancer	4.05e-06	0.000139	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3R1—hematologic cancer	4.04e-06	0.000138	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL3—hematologic cancer	4.01e-06	0.000137	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—hematologic cancer	3.96e-06	0.000135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTPN1—hematologic cancer	3.94e-06	0.000135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTPN11—hematologic cancer	3.89e-06	0.000133	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RASGRP1—hematologic cancer	3.88e-06	0.000133	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HSP90AA1—hematologic cancer	3.86e-06	0.000132	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SYK—hematologic cancer	3.86e-06	0.000132	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—hematologic cancer	3.83e-06	0.000131	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CREB1—hematologic cancer	3.77e-06	0.000129	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—hematologic cancer	3.73e-06	0.000128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT1—hematologic cancer	3.73e-06	0.000128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL2—hematologic cancer	3.69e-06	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6R—hematologic cancer	3.68e-06	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	3.62e-06	0.000124	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—JAK2—hematologic cancer	3.52e-06	0.00012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAP2K1—hematologic cancer	3.5e-06	0.00012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRB2—hematologic cancer	3.49e-06	0.000119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—hematologic cancer	3.48e-06	0.000119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFA—hematologic cancer	3.48e-06	0.000119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KITLG—hematologic cancer	3.43e-06	0.000117	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT5A—hematologic cancer	3.35e-06	0.000115	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—hematologic cancer	3.35e-06	0.000115	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	3.34e-06	0.000114	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN2B—hematologic cancer	3.32e-06	0.000114	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3R1—hematologic cancer	3.29e-06	0.000112	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—hematologic cancer	3.22e-06	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CD86—hematologic cancer	3.21e-06	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—JAK2—hematologic cancer	3.19e-06	0.000109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HES1—hematologic cancer	3.17e-06	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NCOR1—hematologic cancer	3.15e-06	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CSF2—hematologic cancer	3.11e-06	0.000107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF1—hematologic cancer	3.11e-06	0.000107	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—hematologic cancer	3.07e-06	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FOXO1—hematologic cancer	3.07e-06	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—hematologic cancer	3.07e-06	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFRB—hematologic cancer	3.06e-06	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—hematologic cancer	3.03e-06	0.000104	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFRA—hematologic cancer	3.02e-06	0.000103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCG—hematologic cancer	3.01e-06	0.000103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAK1—hematologic cancer	3.01e-06	0.000103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2RA—hematologic cancer	2.81e-06	9.61e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—hematologic cancer	2.79e-06	9.53e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—hematologic cancer	2.78e-06	9.5e-05	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—hematologic cancer	2.73e-06	9.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFB—hematologic cancer	2.71e-06	9.27e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TSC2—hematologic cancer	2.65e-06	9.06e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR3—hematologic cancer	2.55e-06	8.72e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK14—hematologic cancer	2.52e-06	8.63e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—hematologic cancer	2.47e-06	8.47e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FN1—hematologic cancer	2.44e-06	8.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BAD—hematologic cancer	2.41e-06	8.26e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NFKBIA—hematologic cancer	2.41e-06	8.26e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH1—hematologic cancer	2.39e-06	8.18e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CD80—hematologic cancer	2.34e-06	8.02e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—hematologic cancer	2.34e-06	8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—hematologic cancer	2.34e-06	8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—hematologic cancer	2.34e-06	8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTPN11—hematologic cancer	2.3e-06	7.86e-05	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—hematologic cancer	2.27e-06	7.79e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK3—hematologic cancer	2.24e-06	7.67e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREB1—hematologic cancer	2.23e-06	7.62e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—hematologic cancer	2.2e-06	7.52e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL2—hematologic cancer	2.18e-06	7.45e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6R—hematologic cancer	2.17e-06	7.43e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREBBP—hematologic cancer	2.17e-06	7.42e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAP2K1—hematologic cancer	2.07e-06	7.08e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—hematologic cancer	2.06e-06	7.04e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.04e-06	6.97e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—hematologic cancer	2.01e-06	6.89e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF2—hematologic cancer	1.97e-06	6.74e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.94e-06	6.64e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAK2—hematologic cancer	1.89e-06	6.46e-05	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—hematologic cancer	1.86e-06	6.36e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.85e-06	6.33e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—hematologic cancer	1.84e-06	6.3e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.79e-06	6.13e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—hematologic cancer	1.79e-06	6.13e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—hematologic cancer	1.71e-06	5.86e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.68e-06	5.76e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.66e-06	5.69e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—hematologic cancer	1.65e-06	5.64e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—hematologic cancer	1.65e-06	5.63e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—hematologic cancer	1.64e-06	5.6e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—hematologic cancer	1.6e-06	5.49e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—hematologic cancer	1.6e-06	5.48e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.55e-06	5.31e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—hematologic cancer	1.55e-06	5.3e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK8—hematologic cancer	1.51e-06	5.18e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—hematologic cancer	1.51e-06	5.17e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—hematologic cancer	1.48e-06	5.05e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—hematologic cancer	1.44e-06	4.91e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—hematologic cancer	1.4e-06	4.79e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—hematologic cancer	1.38e-06	4.74e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—hematologic cancer	1.38e-06	4.73e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK3—hematologic cancer	1.32e-06	4.53e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—hematologic cancer	1.29e-06	4.4e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—hematologic cancer	1.28e-06	4.39e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—hematologic cancer	1.19e-06	4.07e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	3.74e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—hematologic cancer	1.06e-06	3.62e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	3.46e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—hematologic cancer	9.67e-07	3.31e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—hematologic cancer	8.92e-07	3.05e-05	CbGpPWpGaD
